Curanex Pharmaceuticals Inc CURX
- Market cap
- $7.0M
- P/E
- 0.0×
Follow CURX
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 6.44 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 183.60 |
High Price
|
|||
| — | — | — | — | — | — | — | — | — | — | Employees | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Emp | |||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | 0 | (4) |
EBT
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | — | — | — | — | 0 | (4) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Depreciation
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.60) | (3.40) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.84) | (8.22) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.84) | (8.22) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.76 | 8.80 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | 1 | 1 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | (1) | (10) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | (1) | (10) |
FCF
|
|||
| — | — | — | — | — | — | — | — | 1 | 11 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | 0 | (5) |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | 1 | 11 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (69.85%) |
ROA
|
|||
| — | — | — | — | — | — | — | — | (64.37%) | (42.42%) |
ROIC
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (72.09%) |
ROE
|
|||
Curanex Pharmaceuticals Inc peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| BCLI Brainstorm Cell Therapeutics Inc. | $7.0M | 0.0× | Compare |
| BOLT Bolt Biotherapeutics, Inc. | $6.9M | 0.0× | Compare |
| ENVB Enveric Biosciences, Inc. | $6.9M | 0.0× | Compare |
| LEXX Lexaria Bioscience Corp. | $7.1M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| TRAW Traws Pharma, Inc. | $7.3M | 0.0× | Compare |
| SYBX Synlogic, Inc. | $6.7M | 0.0× | Compare |
| IMNN Imunon, Inc. | $7.3M | 0.0× | Compare |
| CANF Can-Fite Biopharma Ltd | $6.5M | 0.0× | Compare |
Curanex Pharmaceuticals Inc (CURX) key facts
- Curanex Pharmaceuticals Inc (CURX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of September 25, 2026, CURX traded at $4.74, a market capitalization of $7.0 million.
- Return on equity was −72.1% and debt-to-equity 0.00.
Curanex Pharmaceuticals Inc (CURX) Latest News
14 May
Curanex Pharmaceuticals Inc (CURX) reported first quarter 2026 business progress, highlighting Phyto-N's advancement toward planned FDA submission. Phyto-N's advancement toward FDA submission marks a significant regulatory milestone poised to enhance CURX's competitive position and investor sentiment.
8 Apr
Curanex Pharmaceuticals Inc (CURX) announced five additional patient cases supporting the potential of its lead candidate for treating cancer cachexia, advanced cancer supportive care, and severe systemic decline. Additional patient cases build evidence for lead candidate in high-unmet-need areas like cancer cachexia, positively influencing development trajectory and investor sentiment without transformative breakthroughs.
2 Apr
Curanex Pharmaceuticals Inc (CURX) expands its drug development pipeline to include cancer cachexia, targeting a multi-billion-dollar market opportunity and advancing its evolution into a broader therapeutics development company. Pipeline expansion into multi-billion-dollar cancer cachexia market constitutes a major strategic move broadening CURX's therapeutic scope and growth trajectory.
30 Mar
Curanex Pharmaceuticals Inc (CURX) provides business update linked to 2025 Annual Report, with Phyto-N advancing toward planned IND submission. Phyto-N's advancement toward IND submission marks a major pipeline milestone poised to significantly enhance CURX's development trajectory and investor sentiment.
18 Mar
Curanex Pharmaceuticals Inc (CURX) achieved a key preclinical milestone with a favorable toxicology profile at the maximum dose, advancing toward IND submission. Favorable preclinical toxicology at maximum dose de-risks CURX's lead program and accelerates path to human trials, boosting valuation potential.
11 Mar
Curanex Pharmaceuticals Inc (CURX) appoints two veteran industry leaders to its Scientific Advisory Board to strengthen expertise in drug development. Appointing veteran leaders bolsters scientific advisory capabilities, aiding R&D and competitive positioning with moderate impact on future performance.
5 Mar
Curanex Pharmaceuticals Inc (CURX) announces formation of a world-class scientific advisory board comprising leading experts to guide R&D in neuromuscular disorders. Forming a world-class scientific advisory board bolsters Curanex's R&D credibility, accelerates drug development, and enhances competitive positioning in neuromuscular therapeutics.
25 Feb
Curanex Pharmaceuticals Inc (CURX) provides operational update on key regulatory milestones. Key regulatory milestones updates signal potential shifts in CURX's drug approval timelines and market trajectory.
22 Oct
Curanex Pharmaceuticals Inc. has engaged a strategic investor relations firm to improve its investor communications and engagement efforts. This move aims to enhance transparency and foster stronger relationships with current and potential investors, reflecting the company's commitment to effective communication in the financial markets. Enhancing investor communications may moderately influence market sentiment and investor relations but is unlikely to significantly alter the company's overall trajectory.
12 Sep
Curanex Pharmaceuticals Inc. has announced that underwriters have exercised their over-allotment option in connection with the company's recent public offering. This move allows the underwriters to purchase additional shares, potentially increasing the total capital raised during the offering. The exercise of the over-allotment option reflects strong demand for the company's shares and may enhance its financial position. The exercise of the over-allotment option indicates strong market interest, which could positively influence financial performance.
27 Aug
Curanex Pharmaceuticals Inc. has successfully closed its Initial Public Offering (IPO), raising significant capital to support its growth initiatives. The IPO marks a pivotal moment for the company as it aims to enhance its product development and expand its market presence. The funds raised will be utilized for research and development, operational enhancements, and potential strategic acquisitions. Curanex's entry into the public market is expected to increase its visibility and attract new investors, positioning it for future growth. The successful IPO is a major strategic move that could significantly alter the company's trajectory and investor sentiment.
26 Aug
Curanex Pharmaceuticals Inc. has announced the pricing of its initial public offering (IPO), setting the price at $15 per share. The company aims to raise approximately $100 million through the offering, which is expected to enhance its financial position and support its growth initiatives. The IPO is anticipated to be completed soon, subject to customary closing conditions. The IPO represents a significant strategic move that could enhance the company's financial resources and market presence.